A review of epidermal growth factor receptor/HER2 inhibitors in the treatment of patients with non-small-cell lung cancer.
Advanced non-small-cell lung cancer (NSCLC) remains a major global health problem. Although the reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib improves survival in patients with relapsed and recurrent NSCLC, significant limitations exist, including the restriction of clinical efficacy to a small patient subset, poor survival rates, and the development of resistance. Irreversible inhibitors of EGFR and HER2 are novel agents in clinical development that might have the potential to prevent and overcome acquired resistance to first-generation EGFR inhibitors.
Govindan
Ramaswamy
R
Alvin J. Siteman Cancer Center, Washington University School of Medicine, St Louis, MO, USA. rgovinda@im.wustl.edu
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000503:physiopathology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors
D000970:Antineoplastic Agents; D066246:ErbB Receptors; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human